Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

News SummaryMost relevantAll newsSector news 

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
03/24/2012 | 07:59am CEST

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
09/16 DAIICHI SANKYO : Selected for Dow Jones Sustainability Asia Pacific Indices for ..
09/15 DAIICHI SANKYO : Reports from Daiichi Sankyo Add New Data to Findings in Thrombo..
09/15 DAIICHI SANKYO : Researchers at Daiichi Sankyo Target Amphibian Venoms [Synthesi..
09/14 DAIICHI SANKYO : Selected for Dow Jones Sustainability Asia Pacific Indices for ..
09/09 DAIICHI SANKYO : New Findings on Carboxylic Ester Hydrolases from Daiichi Sankyo..
09/09 DAIICHI SANKYO : Galderma and Daiichi Sankyo, Inc. Pledge Support as Silver Spon..
09/01 VEEVA : Daiichi Sankyo Selects Veeva Vault to Streamline Submissions, eTMF, and ..
09/01 DAIICHI SANKYO : Announces Status Relating to Acquisition of Own Shares
08/31 DAIICHI SANKYO : ENSURE-AF Data Support the Efficacy and Safety Profile of Daiic..
08/31 DAIICHI SANKYO : Antiepileptic Drug Vimpat® Tablets 50 mg and 100 mg have been l..
More news
Sector news : Pharmaceuticals - NEC
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/16 Is This The Next Valeant?
08/18 FDA rejects Portola's AndexXa NDA; shares down 18% premarket
07/15 Therapy Focus - Another Try For FGFR Inhibitors
07/14 Amgen and Daiichi Sankyo team up to market biosimilars in Japan
06/01 Nektar Therapeutics inks deal with Daiichi Sankyo for European rights to Onze..
Financials ( JPY)
Sales 2017 918 297 M
EBIT 2017 -
Net income 2017 68 829 M
Finance 2017 310 176 M
Yield 2017 2,83%
P/E ratio 2017 24,00
P/E ratio 2018 24,90
EV / Sales 2017 1,57x
EV / Sales 2018 1,61x
Capitalization 1 751 613 M
More Financials
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 12
Average target price 2 455  JPY
Spread / Average Target -0,63%
Consensus details
EPS Revisions
More Estimates Revisions
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura Vice President-Finance & Accounting Department
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results